Please join us at SLAS 2024 in Boston, MA

Poster Presentations:

Monday, February 5, 2024
Location: Exhibit Halls AB

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging.

Key Takeaways 

Join us January 24 - 26, in Silicon Valley, California at the Santa Clara Convention Center for PMWC 2024.

Panel Discussion:  
Track 3: Oncology Applications Track
January 24 9.00 A.M.-4.45 P.M.

Collaborative Frontiers: Transforming Cancer Care Access and Patient Outcomes (PANEL)